| Literature DB >> 28826890 |
Hui Luo1, Bin Liu1, Lin Zhao1, Jingni He1, Tangzhiming Li1, Lihuang Zha1, Xiaohui Li2, Qiangqiang Qi1, Yuwei Liu1, Zaixin Yu3.
Abstract
Pulmonary vascular adventitia serves as a key regulator of pulmonary vascular remodeling in the pathogenesis of pulmonary arterial hypertension (PAH). Excessive proliferation and differentiation of pulmonary adventitial fibroblasts (PAFs) are proven to be crucial in the pathogenesis of PAH. Galectin-3 (Gal-3) is known as a key fibroblasts activating factor which is involved in the fibrogenesis of several diseases, such as pulmonary fibrosis, vascular fibrosis, and heart failure. Therefore, we seek to investigate the potential role of Gal-3 in regulating PAF cells in the pathogenesis of PAH. Gal-3 plasma concentration was significantly higher in PAH patients. Gal-3 was upregulated in pulmonary artery adventitia of hypoxia-induced PAH rats. Inhibition of Gal-3 with N-Acetyl-D-lactosamine (N-Lac) ameliorated PAH and pulmonary vascular remodeling. Gal-3 can stimulate the proliferation, differentiation, and collagen synthesis of PAFs, which was reversed by N-Lac. Transforming growth factor β1 increased Gal-3 expression in PAFs, whereas N-Lac significantly suppressed transforming growth factor β1-induced proliferation, differentiation, and collagen synthesis of PAFs. Gal-3 serves as a critical regulator in the pathogenesis of PAH by regulating the proliferation, differentiation, and extracellular matrix deposition synthesis of PAFs. Inhibition of Gal-3 may represent a novel therapeutic target for PAH treatment.Entities:
Keywords: Differentiation; TGF-β1; fibrotic response; galectin-3; pulmonary arterial adventitial fibroblasts
Mesh:
Substances:
Year: 2017 PMID: 28826890 DOI: 10.1016/j.jash.2017.07.009
Source DB: PubMed Journal: J Am Soc Hypertens ISSN: 1878-7436